Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation

被引：0
|
作者：
M Staehler
N Haseke
A Roosen
T Stadler
M Bader
M Siebels
A Karl
CG Stief
机构：
[1] Klinikum Grosshadern,Department of Urology, University of Munich
来源：
European Journal of Medical Research | / 15卷
关键词：
renal cell carcinoma; sarcomatoid; chemotherapy; sorafenib; multi-kinase inhibitor; survival; angiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine
    Fujiwara, Yoshiro
    Kiura, Katsuyuki
    Tabata, Masahiro
    Takigawa, Nagio
    Hotta, Katsuyuki
    Umemura, Shigeki
    Omori, Masako
    Gemba, Kenichi
    Ueoka, Hiroshi
    Tanimoto, Mitsune
    ANTI-CANCER DRUGS, 2008, 19 (04) : 431 - 433
  • [22] Radiation therapy and sorafenib: Clinical data and rationale for the combination in metastatic renal cell carcinoma
    Kasibhatla, Mohit
    Steinberg, Peter
    Meyer, Jeffrey
    Ernstoff, Marc S.
    George, Daniel J.
    CLINICAL GENITOURINARY CANCER, 2007, 5 (04) : 291 - 294
  • [23] Temsirolimus in Metastatic Chromophobe Renal Cell Carcinoma after Interferon and Sorafenib Therapy
    Paule, Bernard
    Brion, Nathalie
    ANTICANCER RESEARCH, 2011, 31 (01) : 331 - 333
  • [24] Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
    Dham, A.
    Dudek, A. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Sequential Therapy With Sorafenib and Sunitinib in Renal Cell Carcinoma
    Dudek, Arkadiusz Z.
    Zolnierek, Jakub
    Dham, Anu
    Lindgren, Bruce R.
    Szczylik, Cezary
    CANCER, 2009, 115 (01) : 61 - 67
  • [26] Comparison of Clinical Outcomes between the recurrent advanced Hepatocellular Carcinoma patients with Sorafenib treatment and the patients with Sorafenib plus Interferon combination therapy
    Doi, Hisakazu
    HEPATOLOGY, 2013, 58 : 1251A - 1252A
  • [27] A phase II feasibility study of sorafenib and gemcitabine combination therapy in advanced hepatocellular carcinoma
    Naqi, N.
    Ahmad, S.
    Murad, S.
    Khattak, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [28] Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma
    Maiti, Abhishek
    Nemati-Shafaee, Maryam
    Msaouel, Pavlos
    Pagliaro, Lance C.
    Jonasch, Eric
    Tannir, Nizar M.
    Shah, Amishi Y.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E47 - E57
  • [29] Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma
    Michaelson, D.
    McDermott, D. F.
    Atkins, M. B.
    Cho, D. C.
    Olivier, K. M.
    Schwarzberg, A. B.
    Choueiri, T. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Phase 2 Trial of Sunitinib and Gemcitabine in Patients With Sarcomatoid and/or Poor-Risk Metastatic Renal Cell Carcinoma
    Michaelson, M. Dror
    McKay, Rana R.
    Werner, Lillian
    Atkins, Michael B.
    Van Allen, Eliezer M.
    Olivier, Kara M.
    Song, Jiaxi
    Signoretti, Sabina
    McDermott, David F.
    Choueiri, Toni K.
    CANCER, 2015, 121 (19) : 3435 - 3443
12345